Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACE IT: Neoadjuvant Radio-Immunotherapy in Bladder Cancer
NCT03529890Phase 2Unknown
- Sponsor
- Technical University of Munich
- Start
- Feb 2019
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in bladder cancer, sponsored by Technical University of Munich. Status: unknown.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03529890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03529890.